癌症患者中第四代人类免疫缺陷病毒检测的假反应性结果
该回顾性研究分析了美国德克萨斯大学MD安德森癌症中心2016年3月至2023年1月期间43637例接受第四代HIV-1/2抗体/抗原联合免疫检测的癌症患者,其中293例初筛反应性,排除21例非癌症患者后,272例中78例(29%)为假反应性。多因素分析发现年龄>60岁、女性、种族/ ethnicity、梅毒合并感染及植物生物碱治疗与假反应性相关。作者认为医生应知晓该人群高假反应率,并注意低HIV感染风险者的检测咨询。
要点
- 癌症患者第四代HIV筛查假反应率为29%(78/272)。
- 假反应性患者中26%出现精神困扰,但无人因此延迟癌症治疗。
- 年龄>60岁、女性、植物生物碱治疗与假反应性风险升高相关。
核心结论
- 癌症患者中第四代HIV检测假反应性结果发生率接近三分之一,医生应知晓该人群高假反应率,尤其对低HIV感染风险者需注意检测咨询。
研究设计与样本
- 回顾性研究,纳入美国德克萨斯大学MD安德森癌症中心2016年3月至2023年1月期间接受第四代ARCHITECT HIV-1/2抗体/抗原联合免疫检测且结果反应性的癌症患者,共272例分析。
主要发现
- 43637例患者接受第四代HIV筛查,293例初筛反应性,排除21例非癌症患者后272例中78例(29%)为假反应性。
- 假反应性患者中26%出现精神困扰,无人因此延迟癌症治疗。
- 多因素logistic回归识别5个假反应性预测因素:年龄>60岁(aOR=6.983,P<.0001)、女性(aOR=6.060,P<.0001)、种族/族裔(黑人:aOR=0.274;西班牙裔:aOR=0.236;P=.002)、梅毒合并感染(aOR=0.046,P=.038)、植物生物碱治疗(aOR=2.870,P=.013)。
关键数值与推荐
- 假反应性结果定义基于美国疾病控制与预防中心标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The fourth-generation (4th-gen) human immunodeficiency virus (HIV)-1/2 antibody/antigen (Ab/Ag) combination immunoassay currently used for HIV screening offers greater sensitivity than previous assays, but false-reactive results occur in up to 20% of patients. Large-scale observations in cancer patients are lacking. METHODS: We conducted a retrospective study of cancer patients seen at the University of Texas MD Anderson Cancer Center (March 2016-January 2023) who had reactive 4th-gen ARCHITECT HIV-1/2 Ab/Ag combination immunoassay results. We analyzed characteristics of patients with true-reactive and false-reactive results, defined based on Centers for Disease Control and Prevention criteria. RESULTS: A total of 43 637 patients underwent 4th-gen HIV screening, and 293 had reactive 4th-gen HIV test results. Twenty-one patients were excluded because they did not have cancer. Among the remaining 272 patients, 78 (29%) had false-reactive results. None of these patients experienced delays in their cancer treatment, but 26% experienced mental distress. Multivariate logistic regression analysis identified 5 predictors of having false-reactive results: age >60 years (adjusted odds ratio [aOR], 6.983; P < .0001), female sex (aOR, 6.060; P < .0001), race/ethnicity (Black: aOR, 0.274; Hispanic: aOR, 0.236; P = .002), syphilis coinfection (aOR, 0.046; P = .038), and plant alkaloids therapy (aOR, 2.870; P = .013). CONCLUSIONS: False-reactive 4th-gen HIV test results occur in almost one-third of cancer patients. Physicians should be aware of the high rates of false-reactive HIV screening results in this patient population. These findings may have implications for counseling regarding testing, especially among those at low risk for HIV infection.
引用
- Chiu CY, Mustafayev K, Bhatti MM, et al. False-Reactive Fourth-Generation Human Immunodeficiency Virus Testing in Cancer Patients. Clin Infect Dis. 2024. PMID: 37930789. doi:10.1093/cid/ciad608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。